Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.
The penetration of aztreonam into cerebrospinal fluid was 7 to 15% and 9 to 25%, respectively, in experimental Haemophilus influenzae type b and Escherichia coli K1 meningitis. Aztreonam was effective in reducing the number of organisms in cerebrospinal fluid after single-dose and continuous infusion administration, and the median bactericidal titers in cerebrospinal fluid were 1:32 against both meningeal pathogens.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D001398:Aztreonam; D004927:Escherichia coli Infections / Q000188:drug therapy*; D008297:Male; D008581:Meningitis / Q000188:drug therapy* / Q000209:etiology; D008583:Meningitis, Haemophilus / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D011817:Rabbits
D000900:Anti-Bacterial Agents; D001398:Aztreonam